



Luxembourg, 05/09/2022

Environmental and Social Data Sheet

Overview

Project Name: *MEDINCELL 2 (EGFF)*
 Project Number: *20210248*
 Country: *France*
 Project Description: The promoter is a biopharmaceutical company that offers innovative technologies in drug delivery. The Company's core business consists of designing long acting formulations of drugs, allowing only one administration of active pharmaceutical ingredients with a therapeutic effect ranging from a couple of days to many months.

EIA required: no

Project included in Carbon Footprint Exercise¹: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

Medincell is a pre-commercial biopharmaceutical company developing long acting injectable drugs. The project will support the Company's R&D efforts to develop a proprietary pipeline of clinical and preclinical assets targeting high-unmet medical needs in the areas of neurodegenerative, autoimmune and infectious diseases. The EIB investment will particularly co-finance the development of new formulations and therefore the expansion of the Company's portfolio of programs under development as well as the pre-clinical phases of its proprietary programs.

The project activities neither fall under Annex I nor II of EU Directive 2011/92/EU amended by Directive 2014/52/EU. The project is therefore not subject to the EU EIA Directives. Furthermore, the project will be carried out in existing facilities already authorised for similar activities and volumes.

The Company's R&D facilities and practices are in compliance with relevant national and EU regulations and the Company maintains adequate internal procedures and management practices. The use of animal testing for scientific purposes is minimised and in line with EU Directive 2010/63/EU. In addition, the Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with EU regulation 536/2014. The clinical trials, which are sponsored by the project, are performed under regulated and strictly controlled conditions, in existing specialised facilities, which are

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, 05/09/2022

regularly inspected by competent authorities – the European Medicines Agency (EMA) in Europe and/or national equivalent bodies in the rest of the world (e.g. Food and Drug Administrations (FDA)).

The project has been assessed for Paris alignment and is considered to be aligned both against low carbon and resilience goals.

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel treatments for diseases with currently no cure and limited therapeutic options.

Through the R&D activities and investments, the Company expects to increase its current level of highly skilled personnel, while contributing to European scientific innovation across several areas such as fibrosis and liver diseases, oncology etc., hence fostering and nurturing the vital research community.

The Company has a strong commitment towards promoting employment based on gender equity across all levels with women representing 57% of total employment and 40% of management positions (including the executive management and board members).

Conclusions and Recommendations

The project's activities are neither listed under Annex I nor II of the EU EIA Directive 2011/92/EU amended by Directive 2014/52/EU, and the research activities will be executed in existing and authorised research facilities. The Company has effective policies and operating procedures in place, which are in line with industry standards.

Considering the above, the project is considered acceptable for Bank financing in environmental and social terms.